Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AGN-210961 vs Bimatoprost in Glaucoma or Ocular Hypertension
NCT01110499Phase 2Completed
- Sponsor
- Allergan
- Start
- Jun 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aganepag isopropyl in ocular hypertension and primary open-angle glaucoma (POAG) (8 arms), sponsored by Allergan. Primary endpoint: Intraocular Pressure at Day 7. Started Jun 2010; status: completed.
02
Drugs
aganepag isopropyl
03
Conditions
ocular hypertensionprimary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT01110499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01110499.